Similarly, Lactobacillus reuteri administration inhibits the progression of ICI-associated colitis in mice administered DSS in their drinking water and treated with anti-CTLA-4 and anti-PD-1 immunotherapy (140). The gene discussed is CTLA4; the disease is colitis.